Abstract:K-Ras is the most commonly mutated oncogene in human cancer, yet direct small-molecule targeting of K-Ras mutants has been mostly unsuccessful until recently. The discovery of an allosteric pocket under Switch-II with covalent cysteine-crosslinking molecules has allowed for the development of targeted therapies that selectively engage the highly reactive acquired cysteine in the K-Ras(G12C) mutation without affecting the wild-type protein. Sotorasib and adagrasib, two advanced Switch-II Pocket inhibitors, have received FDA approval to treat K-Ras(G12C)-driven non-small cell lung cancer. However, the most frequent K-Ras mutation G12D particularly prevalent in pancreatic ductal adenocarcinoma has remained untargetable with covalent drugs due to the poor nucleophilicity of the somatic aspartate residue. Here we present a set of malolactone-based electrophiles which exploit ring strain to crosslink K-Ras(G12D) at the mutant aspartate to form stable covalent complexes. Structural insights from x-ray crystallography and exploitation of the stereoelectronic requirements for attack of the electrophile allowed development of a substituted malolactone which resisted attack by aqueous buffer but rapidly crosslink with the aspartate-12 of K-Ras in both GDP- and GTP-state. The signaling-competent GTP-state targeting allowed effective suppression of downstream signaling and proliferation of cancer cells harboring K-Ras(G12D) mutation, and tumor growth of cell line-derive xenograft in mice. Our results demonstrate the rational design of covalent inhibitors to target a non-catalytic carboxylic acid side chain in K-Ras(G12D) which has resisted traditional drug discovery efforts. ### Competing Interest Statement K.M.S., Z.Z., and Q.Z. are inventors on patents related to covalent K-Ras(G12D) inhibitors reported here. K.M.S. is an inventor on patents owned by University of California San Francisco covering KRAS targeting small molecules licensed to Araxes, Erasca and Novartis. K.M.S. has consulting agreements for the following companies, which involve monetary and/or stock compensation: Revolution Medicines, Black Diamond Therapeutics, BridGene Biosciences, Denali Therapeutics, Dice Molecules, eFFECTOR Therapeutics, Erasca, Novartis, Genentech/Roche, Janssen Pharmaceuticals, Kumquat Biosciences, Kura Oncology, Mitokinin, Type6 Therapeutics, Nested Therapeutics, Vevo, Wellspring Biosciences (Araxes Pharma), Ikena, Initial Therapeutics and BioTheryX.

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

Developing Small Molecules that Inhibit K-Ras/GTP Binding Based on New Affinity Measurements

GTP-State-Selective Cyclic Peptide Ligands of K-Ras(G12D) Block Its Interaction with Raf

Reversible Small Molecule pan-Ras Inhibitors Display Tunable Affinity for the Active and Inactive forms of Ras.

Targeting Ras-, Rho-, and Rab-family GTPases via a conserved cryptic pocket

KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge

In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C

Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics

K-Ras G-domain binding with signaling lipid phosphatidylinositol (4,5)-phosphate (PIP2): membrane association, protein orientation, and function

Revealing the mechanism of action of a first-in-class covalent inhibitor of KRASG12C (ON) and other functional properties of oncogenic KRAS by 31P NMR

Insight of the molecular mechanism of inhibitors located at different allosteric sites regulating the activity of wild type and mutant KRAS (G12)

KRAS is Vulnerable to Reversible Switch-Ii Pocket Engagement in Cells

A New Dawn for Targeted Cancer Therapy: Small Molecule Covalent Binding Inhibitor Targeting K-Ras (G12C)

Strain-release alkylation of Asp12 enables mutant selective GTP-state targeting of K-Ras(G12D)

Conformational Transformation of Switch Domains in GDP/K-Ras Induced by G13 Mutants: an Investigation Through Gaussian Accelerated Molecular Dynamics Simulations and Principal Component Analysis.

Pharmacologic restoration of GTP hydrolysis by mutant RAS

Biophysical and Biochemical Characterization of Structurally Diverse Small Molecules Hits for KRAS Inhibition

Development of a Nucleotide Exchange Inhibitor That Impairs Ras Oncogenic Signaling.

Pan-KRAS inhibitor disables oncogenic signalling and tumour growth

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor

Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in Cancer Therapy